B·R·A·H·M·S Biomarkers: Preeclampsia Management

Discover the power of biomarker testing on KRYPTOR for improved preeclampsia management  

Preeclampsia is a life-threatening hypertensive disorder occurring during pregnancy which affects 3-4% of all pregnancies in the U.S.1 The condition most often occurs after 20 weeks of gestation and can only be cured by delivery of the baby.2 Preeclampsia contributes largely to maternal and fetal morbidity and mortality. 

 

Placental biomarkers, sFlt-1 and PlGF, play a pivotal role in the risk assessment and clinical management of preeclampsia.

 

Experience the confidence that comes with our complete solution, backed by years of expertise and unwavering commitment to delivering excellence in prenatal care.

Understand best practices for preeclampsia

preeclampsia-spotlight

Biomarker solutions for preeclampsia management

Use only the highest levels of precision in your lab

B·R·A·H·M·S Biomarkers for preeclampsia testing allow your lab to run with the highest precision and most reliable results.

Choose the highest quality for your patients

B·R·A·H·M·S Biomarkers for preeclampsia management help provide patients with the most accurate and precise risk calculations available.

Choose the B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System

B·R·A·H·M·S Assays for preeclampsia risk assessment provide outstanding lot-to-lot stability and high precision.
Only B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System is cleared for use in the US. 

Unlock the power of precision and reliability

B·R·A·H·M·S KRYPTOR compact PLUS is a fully automatic, closed laboratory analysis system employing Nobel-Prize winning TRACE technology.

Discover innovative biomarker solutions

B·R·A·H·M·S Biomarker solutions help to improve the early diagnosis and treatment of life-threatening diseases.

Explore helpful resources

Find resources to learn more about B·R·A·H·M·S Biomarkers for preeclampsia screening and the benefits of implementing these assays in your laboratory and clinic. 

References

1. Burwick RM, Rodriguez MH. Angiogenic Biomarkers in Preeclampsia. Obstet Gynecol. 2024 Apr 1;143(4):515-523. 

2. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstetrics and Gynecology. 2020;135(6):1492-1495.

Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.

 

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.

 

KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.